www.veozahhcp.com Open in urlscan Pro
2600:9000:25e8:3a00:f:ecd0:97c0:93a1  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Full Prescribing Information
 * Important Safety Information
 * Women’s Health Resources
 * Medical Inquiry
 * Patient Site
 * Request a Rep

 * Mechanism of Action
 * Efficacy & Safety
   * Study Design
   * Efficacy
   * Safety
 * Dosing
 * Get Patients Started
   * VEOZAH Support SolutionsSM
 * Resources
 * Samples

Full Prescribing Information Important Safety Information
CLOSE
HOME

 * HOME
 * MECHANISM OF ACTION
 * EFFICACY & SAFETY
   MAIN MENU
    * STUDY DESIGN
    * EFFICACY
    * SAFETY

 * DOSING
 * GET PATIENTS STARTED
   MAIN MENU
    * VEOZAH Support SolutionsSM

 * RESOURCES
 * SAMPLES
 * REQUEST A REP
 * WOMEN’S HEALTH RESOURCES
 * MEDICAL INQUIRY
 * PATIENT SITE

×


YOU ARE ABOUT TO LEAVE THIS WEBSITE.

By clicking “Continue”, you will leave this site and enter VEOZAHsamples.com.

Cancel Continue

NOTE: The website you are linking to is neither owned nor controlled by
Astellas. You should review the applicable terms and polices, including privacy
and data-gathering policies, of any website to which you navigate.



×


YOU ARE ABOUT TO LEAVE THIS WEBSITE.

By clicking “Continue”, you will open AstellasAnswers.com.

Cancel Continue

This website is funded and developed by Astellas Pharma US, Inc.




THIS WEBSITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

I certify that I am a healthcare professional in the US.

NO YES




STAY UP TO DATE
 * 
 * 
 * 
 * 
 * 

For the treatment of moderate to severe Vasomotor Symptoms (VMS) due to
menopause, commonly referred to as hot flashes and night sweats1,2

FighttheFire
WITH NONHORMONAL VEOZAH

New VEOZAH directly targets a source of VMS—specific neurons in the
hypothalamus. Give your patients another way to treat the heat day and night.1



EXPLORE THE MOA



WATCH THE MECHANISM OF ACTION (MOA)

VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks
NKB from binding on KNDy neurons to help reduce heat signals that trigger
VMS.1,3

SEE VIDEO

KNDy=kisspeptin/neurokinin B/dynorphin, NKB=neurokinin B.



TRANSCRIPT

KNDy=kisspeptin/neurokinin B/dynorphin, NKB=neurokinin B.


MECHANISM OF ACTION

 * Off
 * English


04:43

 TRANSCRIPT


MECHANISM OF ACTION


MOA VIDEO TRANSCRIPT

4 mins 43 secs 

Moderate to severe Vasomotor Symptoms, also known as VMS or hot flashes and
night sweats, are the most bothersome symptoms of menopause. Growing evidence
has led to a different treatment pathway that directly targets a source of VMS
in the hypothalamus.

Meet VEOZAH™ (fezolinetant). VEOZAH is not a hormone. It is a first-in-class
NK3R antagonist that works differently to directly block a mechanism that
triggers VMS.

KNDy neurons in the hypothalamus are inhibited by estrogen and stimulated by the
neuropeptide, NKB. This balance contributes to body temperature regulation.
During the menopause transition, estrogen decline disrupts this balance with
NKB. Unopposed, NKB signaling causes heightened KNDy activity and altered
activity on the thermoregulatory center, resulting in VMS.

VEOZAH directly targets this source of VMS. By selectively binding to NK3R,
VEOZAH blocks NKB, modulating neuronal activity in the thermoregulatory center
to reduce heat signaling that triggers hot flashes and night sweats.

It’s time to put the mechanism of VEOZAH to work for your appropriate VMS
patients.

INDICATIONS AND USAGE

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for
the treatment of moderate to severe vasomotor symptoms due to menopause.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

 1. VEOZAH is contraindicated in women with any of the following:
 2. Known cirrhosis
 3. Severe renal impairment or end-stage renal disease
 4. Concomitant use with CYP1A2 inhibitors

WARNINGS AND PRECAUTIONS

Hepatic Transaminase Elevation

Elevations in serum transaminase [alanine aminotransferase (ALT) and/or
aspartate aminotransferase (AST)] levels > 3x the upper limit of normal (ULN)
occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo
in three clinical trials. No serum elevations in total bilirubin (> 2x ULN)
occurred.

Women with ALT or AST elevations were generally asymptomatic. Transaminase
levels returned to pretreatment levels (or close to these) without sequelae with
dose continuation, and upon dose interruption, or discontinuation. Women with
cirrhosis were not studied.

Perform baseline bloodwork to evaluate for hepatic function and injury prior to
VEOZAH initiation. Do not start VEOZAH if concentration of ALT or AST is ≥ 2x
ULN or if the total bilirubin is elevated (e.g., ≥ 2x ULN) for the evaluating
laboratory. If baseline hepatic transaminase evaluation is < 2x ULN and the
total bilirubin is normal, VEOZAH can be started. Perform follow-up evaluations
of hepatic transaminase concentration at 3 months, 6 months, and 9 months after
initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing
of the skin or eyes) suggest liver injury.

ADVERSE REACTIONS

The most common adverse reactions with VEOZAH ≥ 2% and > placebo (VEOZAH % vs.
placebo %) are: abdominal pain (4.3% vs. 2.1%), diarrhea (3.9% vs. 2.6%),
insomnia (3.9% vs. 1.8%), back pain (3.0% vs. 2.1%), hot flush (2.5% vs. 1.6%),
and hepatic transaminase elevation (2.3% vs. 0.8%).

Please see accompanying full Prescribing Information for VEOZAH™ (fezolinetant).

 BACK TO VIDEO

OFFER YOUR PATIENTS A DIFFERENT OPTION TO MANAGE VMS WITH VEOZAH.1,3


EFFICACY AND SAFETY

VMS RELIEF DAY AND NIGHT

VEOZAH demonstrated statistically significant reductions from baseline in the
frequency and severity of moderate to severe VMS over 24 hours compared to
placebo, at weeks 4 and 12.1*

SEE THE DATA

The efficacy of VEOZAH was studied in 1022 women who received 1 of 2 doses of
VEOZAH (including 45 mg) in two 12-week, randomized, placebo-controlled,
double-blind Phase 3 studies. In each of these 2 trials, after the first 12
weeks, women on placebo were rerandomized to VEOZAH for a 40-week extension to
evaluate safety for up to 52 weeks total exposure.1




SAVINGS AND SUPPORT

VEOZAH SUPPORT SOLUTIONSSM

Help your patients access VEOZAH and save on prescriptions.†

GET STARTED

†Subject to eligibility. Restrictions may apply.


Sign up for exclusive VEOZAH updates and product information

Survey
×
What is your primary medical specialty? [Select one]
 * General practice/ family practice/ internal medicine
 * Nurse practitioner
 * Physician assistant or associates
 * Obstetrics and gynecology/ urogynecology
 * Other specialty physician
 * Healthcare office staff not prescribing drugs
 * None of these

Crafted with Pulse Insights

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

 1. Known cirrhosis
 2. Severe renal impairment or end-stage renal disease
 3. Concomitant use with CYP1A2 inhibitors

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for
the treatment of moderate to severe vasomotor symptoms due to menopause.

INDICATIONS AND USAGE

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for
the treatment of moderate to severe vasomotor symptoms due to menopause.

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

 1. Known cirrhosis
 2. Severe renal impairment or end-stage renal disease
 3. Concomitant use with CYP1A2 inhibitors

WARNINGS AND PRECAUTIONS

Hepatic Transaminase Elevation

Elevations in serum transaminase [alanine aminotransferase (ALT) and/or
aspartate aminotransferase (AST)] levels > 3x the upper limit of normal (ULN)
occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo
in three clinical trials. No serum elevations in total bilirubin (> 2x ULN)
occurred. Women with ALT or AST elevations were generally asymptomatic.
Transaminase levels returned to pretreatment levels (or close to these) without
sequelae with dose continuation, and upon dose interruption, or discontinuation.
Women with cirrhosis were not studied.

Perform baseline bloodwork to evaluate for hepatic function and injury prior to
VEOZAH initiation. Do not start VEOZAH if concentration of ALT or AST is ≥ 2x
ULN or if the total bilirubin is elevated (e.g., ≥ 2x ULN) for the evaluating
laboratory. If baseline hepatic transaminase evaluation is < 2x ULN and the
total bilirubin is normal, VEOZAH can be started. Perform follow-up evaluations
of hepatic transaminase concentration at 3 months, 6 months, and 9 months after
initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing
of the skin or eyes) suggest liver injury.

ADVERSE REACTIONS

The most common adverse reactions with VEOZAH ≥ 2% and > placebo (VEOZAH % vs.
placebo %) are: abdominal pain (4.3% vs. 2.1%), diarrhea (3.9% vs. 2.6%),
insomnia (3.9% vs. 1.8%), back pain (3.0% vs. 2.1%), hot flush (2.5% vs. 1.6%),
and hepatic transaminase elevation (2.3% vs. 0.8%).



Please click here for full Prescribing Information for VEOZAH™ (fezolinetant).



References: 1. VEOZAH [package insert]. Northbrook, IL: Astellas Pharma US, Inc.
2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et
al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The
North American Menopause Society, 2019:43-55. 3. Depypere H, Lademacher C,
Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms
associated with menopause. Expert Opin Investig Drugs 2021;30(7):681-94.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

 1. Known cirrhosis
 2. Severe renal impairment or end-stage renal disease
 3. Concomitant use with CYP1A2 inhibitors

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for
the treatment of moderate to severe vasomotor symptoms due to menopause.

INDICATIONS AND USAGE

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for
the treatment of moderate to severe vasomotor symptoms due to menopause.

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

 1. Known cirrhosis
 2. Severe renal impairment or end-stage renal disease
 3. Concomitant use with CYP1A2 inhibitors

WARNINGS AND PRECAUTIONS

Hepatic Transaminase Elevation

Elevations in serum transaminase [alanine aminotransferase (ALT) and/or
aspartate aminotransferase (AST)] levels > 3x the upper limit of normal (ULN)
occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo
in three clinical trials. No serum elevations in total bilirubin (> 2x ULN)
occurred. Women with ALT or AST elevations were generally asymptomatic.
Transaminase levels returned to pretreatment levels (or close to these) without
sequelae with dose continuation, and upon dose interruption, or discontinuation.
Women with cirrhosis were not studied.

Perform baseline bloodwork to evaluate for hepatic function and injury prior to
VEOZAH initiation. Do not start VEOZAH if concentration of ALT or AST is ≥ 2x
ULN or if the total bilirubin is elevated (e.g., ≥ 2x ULN) for the evaluating
laboratory. If baseline hepatic transaminase evaluation is < 2x ULN and the
total bilirubin is normal, VEOZAH can be started. Perform follow-up evaluations
of hepatic transaminase concentration at 3 months, 6 months, and 9 months after
initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing
of the skin or eyes) suggest liver injury.

ADVERSE REACTIONS

The most common adverse reactions with VEOZAH ≥ 2% and > placebo (VEOZAH % vs.
placebo %) are: abdominal pain (4.3% vs. 2.1%), diarrhea (3.9% vs. 2.6%),
insomnia (3.9% vs. 1.8%), back pain (3.0% vs. 2.1%), hot flush (2.5% vs. 1.6%),
and hepatic transaminase elevation (2.3% vs. 0.8%).

Please click here for full Prescribing Information for VEOZAH™ (fezolinetant).

References: 1. VEOZAH [package insert]. Northbrook, IL: Astellas Pharma US, Inc.
2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et
al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The
North American Menopause Society, 2019:43-55. 3. Depypere H, Lademacher C,
Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms
associated with menopause. Expert Opin Investig Drugs 2021;30(7):681-94.


 * Stay Up to Date
 * Request a Rep
 * Medical Information
 * Privacy Policy
 * Legal Disclaimer
 * Sitemap
 * Contact Us
 * Accessibility

Astellas and the flying star logo are registered trademarks of Astellas Pharma
Inc. VEOZAH and the Wave logo are trademarks of Astellas US LLC. VEOZAH Support
Solutions℠, a component of Astellas Pharma Support Solutions℠, is a service mark
of Astellas US LLC.

This website is intended for US Healthcare Professionals only.

©2023 Astellas Pharma US, Inc. All rights reserved. 054-0017-PM 06/23